• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Clinical Pharmacology In Drug Development(Electronic)

    Clinical Pharmacology In Drug Development(Electronic)

    JournalISSN 2160-7648eISSN 2160-7648中科院 医学 4区

    年发文量

    研究主题

    论文(2053)

    排序
    1Pharmacogenomics As a Design Input in Early‐Phase Drug Development
    Amalia M. Issa
    2026
    引用
    AI阅读
    加入学术空间
    2Comparability of Pharmacokinetics, Safety, and Tolerability of Canakinumab Administration with One Injection (200 Mg) of Pre‐Filled Syringe or Auto‐Injector Versus Two Injections (150 and 50 Mg) of Pre‐Filled Syringe in Healthy Subjects
    Abhijit Chakraborty, Anshu Marathe, Jong Bong Lee, Kari Wiedinger, Britta Zehnpfennig,Carole Schuhler, Simantini Eddy,Michelle Quinlan

    Abstract This phase 1, randomized, open‐label, single‐dose, parallel‐group study aimed to describe the pharmacokinetic (PK) comparability and safety of canakinumab administered as a single 200 mg subcutaneous injection via pre‐filled syringes assembled within a needle safety device (PFS‐NSD) by HCP and auto‐injector (AI) by subject self‐administration versus two injections of 150 + 50 mg via PFS‐NSD by HCP. Healthy adults (18–55 years) were allocated to three arms: canakinumab 150 + 50 mg (PFS‐NSD; n = 78), canakinumab 200 mg (AI; n = 76), and canakinumab 200 mg (PFS‐NSD; n = 76). Multiplicity was addressed as two tests were compared with the same reference. Primary PK parameters were comparable across arms. The geometric mean ratios and 95% CI values of AUC inf , AUC last , and C max were within bioequivalence limits of 0.80‐1.25 for both comparisons: (a) canakinumab 200 mg AI versus canakinumab 150 + 50 mg PFS‐NSD and (b) canakinumab 200 mg PFS‐NSD versus canakinumab 150 + 50 mg PFS‐NSD. Median T max was comparable: 7, 9, and 7 days for canakinumab 150 + 50 mg PFS‐NSD, 200 mg AI, and 200 mg PFS‐NSD, respectively. Exploratory post‐hoc analyses, assessing the impact of pause during the pandemic (N = 131 subjects recruited pre‐pandemic) and evaluating partial AUC 4weeks , suggested similar results. Canakinumab was well‐tolerated, and no treatment‐induced immunogenicity was observed.

    2026
    引用
    AI阅读
    加入学术空间
    3A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants
    Joseph F. Grippo, Anja Pfaff,Zhongli Xu, Isabell Otto,Claus Thielert, Mihaly Imre, Rui Liu, Wantanee Phuapradit, Yazhong Pei, Cuie Chen,Maria Habel,Renfeng Guo,

    Abstract This was a first‐in‐human, single‐center, Phase 1 study of izicopan (formerly INF904), a potent oral, second‐generation small molecule antagonist of C5aR1, in healthy adults. Participants were randomized to a single oral dose of izicopan 3–240 mg or matched placebo (single ascending dose [SAD]), or multiple doses of izicopan 30 mg once daily (QD), 30 or 90 mg twice daily (BID), or matched placebo, for 14 days (multiple ascending dose [MAD]). In the SAD study, izicopan plasma concentration increased with dose from 3 to 240 mg; the mean maximum plasma concentration (C max ) was 21.5–1216.0 ng/mL, reached at a median time (t max ) of 3.5–6.0 h, followed by a biphasic decline. In the MAD study, a steady state appeared to have been reached within 14 days, and AUC 0‐tau exhibited an accumulation ratio of ∼2‐fold following BID dosing, suggesting an effective half‐life of ∼12 h. In an ex vivo whole blood PD assay, izicopan resulted in >90% blockade of CD11b upregulation by recombinant human C5a across almost all dose cohorts from Days 2–15. Adverse events were mild or moderate in severity. In conclusion, izicopan was safe across all single and multiple doses evaluated. Sufficient izicopan exposure was achieved rapidly to exert >90% blockade of C5a‐C5aR1 signaling.

    2026
    引用
    AI阅读
    加入学术空间
    4Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus MproInhibitor, in Healthy Adults: A Randomized, Single- and Multiple-Dose Study
    Jart A. F. Oosterhaven, Jonathan Trolander,Lidiya Bebrevska, Hilmar Schiller, Begum Alaybeyoglu, Suzanne Gaudet, Allison Claas, Kamal Kumar Balavenkatraman, Renee Bergeron, Fernanda V. Duraes, Frederique Chaperon, Swati Ghanshani,

    Antiviral therapy is needed to address acute coronavirus disease. EGT710 is a novel low-molecular-weight inhibitor of the coronavirus main protease (Mpro). This first-in-human study evaluated the safety, tolerability, and pharmacokinetics of EGT710 in healthy adults. The study conducted in the Netherlands involved three parts: a blinded, placebo-controlled, 3:1 randomized, single ascending dose Part A (n = 39); a multiple ascending dose Part B (n = 31); and an open-label, three-period, six sequence, randomized, cross-over Part C (n = 18) to evaluate food and formulation effects on EGT710 bioavailability. EGT710 was well tolerated. All adverse events (AEs) were mild (Grade 1), with no serious AEs or discontinuations. Aside from mild gastrointestinal AEs associated with EGT710, AE frequency was similar between groups with no dose-dependent or dose-limiting adverse effects. EGT710 was rapidly absorbed (median Tmax 2.0 h), showed sub-proportional AUC and Cmax increases and no significant accumulation with daily dosing. Bioavailability was comparable between suspension and capsule formulations. Food increased Cmax by 20% and AUC by 27%. EGT710 700 mg once daily for 7 days modestly induced CYP3A4 activity but had no effect on organic anion transporting polypeptide (OAT1/3) activity. Oral EGT710 (capsule and suspension) was safe and well tolerated, with pharmacokinetics that support further development as a treatment for coronavirus disease.

    2026
    引用
    AI阅读
    加入学术空间
    5A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects
    Jianxin Wang, Kai Gu, Mingxuan Zhang, Miao Yu, Pei Zhao, Jing Yu, Xiaohong Guo, Yating Bai, Jie Liu, Xiaoli Wang, Xiaolai Yang

    Enzalutamide is an oral second-generation androgen receptor inhibitor used for advanced prostate cancer. This study evaluated the pharmacokinetics (PK), bioequivalence (BE), and safety of a newly developed generic enzalutamide soft capsule (test) compared with the reference product (XTANDI) in healthy Chinese adults under fasting and fed conditions. A single-center, randomized, open-label, two-period, two-sequence, crossover study was conducted in 72 male participants (36 fasting and 36 fed). Each participant received a single 40-mg dose of test or reference formulation, separated by a 34-day washout. Blood samples were collected up to 72 h post-dose. PK parameters (Cmax and AUC0-72 h) were calculated using non-compartmental analysis. BE was assessed by 90% confidence intervals (CIs) of geometric mean ratios (GMRs). Safety was monitored throughout the study. In both fasting and fed conditions, the 90% CIs of GMRs for Cmax and AUC0-72 h were within the predefined 80%-125% BE range. Both formulations exhibited a favorable single-dose safety profile, with no serious adverse events reported. The test enzalutamide soft capsule is bioequivalent to the reference product in healthy Chinese volunteers, demonstrating similar PK profiles and safety. This study provides population-specific PK evidence supporting the clinical use of the generic formulation in China.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2053 篇论文

    高被引作者

    作者引用发文
    Yamazaki Takao3717
    Townsend Robert W3717
    Kowalski Donna3717
    Christopher Lademacher3717
    Amit Desai3717
    David J. Greenblatt30534
    Helene Pearlman2734
    Corrie Howieson2385
    Kato Kota1896
    Kenneth C Lasseter1734

    高产作者

    作者引用发文
    David J. Greenblatt30534
    Darpo Borje9722
    Hongqi Xue4820
    Ramesh Boinpally9518
    Marian Iwamoto7218
    Kyle Matschke15917
    Bing Xu1315
    Karthik Venkatakrishnan10214
    Ying Wang4214
    G Fang-Liang414

    相关期刊

    Clinical pharmacokinetics
    European Journal of Clinical Pharmacology
    European journal of drug metabolism and pharmacokinetics
    Drugs in R&D
    Expert opinion on drug safety
    Expert Opinion on Drug Metabolism & Toxicology
    Clinical drug investigation
    Expert review of clinical pharmacology
    Journal Of Clinical Pharmacology
    International Journal of Clinical Pharmacology and Therapeutics